Treatment Of Herpes Simplex Labialis Research Articles

Interventions for treatment of herpes simplex labialis (cold sores on the lips)

Interventions for treatment of herpes simplex labialis (cold sores on the lips)

Clinical Study on the Effectiveness of Three Products in the Treatment of Herpes Simplex Labialis

Herpes simplex labialis (HSL) is a viral disease that affects the perioral region. No guidelines recommending an effective treatment exist. The treatment of HSL with three different products was examined. Herpatch Serum, a film-forming patch, was compared to Compeed Patches, a set of semiocclusive hydrocolloid patches, and Zovirax Cream (ingredient: 5% acyclovir). In this prospective, randomized, examiner-blind study, 180 patients with recurrent HSL were split into three groups (Compeed: n = 60, Herpatch: n = 60, Zovirax: n = 60) and examined within 24 hours of HSL outbreak (DRKS Registration No.: DRKS00007786). The primary endpoint was healing time. The secondary endpoints were the reaction rate and quality of therapy evaluated by the Clinician’s Global Assessment of Therapy (CGAT) and the Subject’s Global Assessment of Therapy (SGAT) (0 = no response; 10 = excellent response), respectively. There was no significant difference among the healing times for the different products. The mean (95% confidence interval) was 9.67 days (9.11–10.22) for Compeed, 9.30 days (8.75–9.85) for Herpatch, and 9.80 days (9.30–10.30) for Zovirax. The reaction rate and quality of therapy (CGAT and SGAT) of Herpatch were significantly higher than those of Compeed and Zovirax. Within the study limitations, Herpatch proved to be an effective, non-antiviral alternative in the treatment of HSL.

Efficacy of a topical herbal and mineral formulation (Dynamiclear) for the treatment of herpes simplex labialis in the community setting: study protocol for a randomised, double-blind placebo-controlled trial

IntroductionHerpes simplex labialis (HSL) is a common infection that can cause painful lesions on the oral mucosa, commonly referred to as cold sores. Current biomedical treatments include topical aciclovir, which...

Kanuka honey versus aciclovir for the topical treatment of herpes simplex labialis: a randomised controlled trial

ObjectiveTo compare New Zealand medical grade kanuka honey with topical aciclovir for the treatment of herpes simplex labialis.DesignProspective parallel randomised controlled open-label superiority trial.Setting76 community pharmacies across New Zealand between...

A Systematic Review on the Efficacy of Topical Acyclovir, Penciclovir, and Docosanol for the Treatment of Herpes Simplex Labialis

Background: Herpes simplex labialis is a common skin condition caused by the herpes simplex virus. The prescription of antivirals for the treatment of herpes labialis is common. The objective of this study was to conduct a systematic review of the available evidence on the treatment of herpes simplex labialis with U.S. Food and Drug Administration (FDA)-approved topical antibiotics. Methods: The literature search included searches of PubMed, Google Scholar, and Scopus. This review included studies that examined herpes labialis lesions and treatment with topical acyclovir, penciclovir, or docosanol in at least one of the study arms. Results: Of the 1,485 papers initially identified, 20 papers representing 19 randomised controlled trials and one quasi-randomised trial met the inclusion criteria for the systematic review. Conclusion: Our systematic review of the clinical studies performed on the three topical antiherpetics, acyclovir, penciclovir, and docosanol, showed that their efficacy compared to placebo is marginal at best (shortening the duration of pain by <24 hours), although the three topical antiherpetic drugs have no serious adverse reactions and are safe to use.

Protocol for a randomised controlled trial of 90% kanuka honey versus 5% aciclovir for the treatment of herpes simplex labialis in the community setting

IntroductionWorldwide, about 90% of people are infected with the herpes simplex virus, 30% of whom will experience recurrent herpes simplex labialis, commonly referred to as ‘cold sores’, which can last...

Treatment of herpes simplex labialis in macule and vesicle phases with photodynamic therapy. Report of two cases

a Integrated Clinic Discipline, Department of Stomatology, School of Dentistry, University of Sao Paulo (USP), 05508-000 Sao Paulo, SP, Brazil b Special Laboratory of Lasers in Dentistry (LELO), Department of Restorative Dentistry, School of Dentistry — University of Sao Paulo (USP), 05508-000 Sao Paulo, SP, Brazil c Department of Biomaterials and Oral Biology, School of Dentistry, University of Sao Paulo (SSP), 05508-000 Sao Paulo, SP, Brazil Available online 10 March 2015

Evaluation of the efficacy of low-level light therapy using 1072 nm infrared light for the treatment of herpes simplex labialis

Recent research has shown that low-level light therapy (LLLT) using 1072 nm infrared light is effective in reducing the duration of herpes simplex labialis (HSL) episodes and enhancing the healing process. This was a prospective, randomized, placebo-controlled, clinical trial to evaluate the efficacy of a 1072 nm light-emitting diode device for the treatment of HSL. In total, 87 patients with recurrent HSL were recruited and randomly divided into two groups. Subjects received a 3-min treatment with either 1072 nm infrared light therapy or placebo (sham) light therapy three times/day for 2 days. The devices used for both groups were identical in appearance and could not be differentiated by volunteers or researchers, and 1072 nm light is invisible to the human eye. The primary endpoint was healing time, which was taken as the time for the HSL lesions to resolve fully and for the underlying skin to become completely re-epithelialized, and the secondary endpoint was lesion crusting. The median time to healing for the active group was 129 h, compared with 177 h for the control group, which was significant (P = 0.01). There was no difference between the two groups for median time to lesion crusting (P = 0.66). Compared with placebo treatment, the treatment of HSL lesions with 1072 nm infrared light significantly reduced healing time.

Interventions for treatment of herpes simplex labialis (cold sores on the lips)

Interventions for treatment of herpes simplex labialis (cold sores on the lips)

Valacyclovir and topical clobetasol gel for the episodic treatment of herpes labialis: a patient‐initiated, double‐blind, placebo‐controlled pilot trial

Treatment of herpes simplex labialis (HSL) has been associated with modest benefits. This difficulty results from the rapid resolution of the disease accomplished by the immune system, which narrows the window of therapeutic opportunity. The immune response is also responsible for important clinical manifestations, including oedema and pain. The dual role of immune responses (protection, pathology) is well recognized in other infectious diseases. The addition of corticosteroids to antimicrobial agents has been associated with improvement in some of these diseases. We evaluated the combination of oral valacyclovir plus topical clobetasol compared to placebo for recurrent HSL. Eighty-one subjects were screened, randomized, and dispensed medication (valacyclovir 2 g orally twice daily phiomicronrho 1 day and clobetasol gel 0.05% twice daily for 3 days). Forty-two patients developed a recurrence and initiated treatment. There were more aborted lesions in the valacyclovir-clobetasol arm compared to placebo-placebo (50% vs.15.8%, P = 0.04). Combination therapy reduced the mean maximum lesion size (9.7 vs. 54 mm(2), P = 0.002) and the mean healing time of classical lesions (5.8 vs. 9.3 days, P = 0.002). We created a composite statistic, area-under-the-curve (AUC) of classical lesion size versus time. There was a reduction in the AUC in the combination arm compared with placebo (23 vs. 193 mm(2), P < 0.001). Adverse events were minimal. Secondary and post-treatment recurrences were not increased by combination therapy. This pilot study supports the addition of topical corticosteroids to an oral antiviral agent for the treatment of HSL. Larger studies need to confirm the safety and efficacy of this approach.

Randomized clinical study comparing Compeed® cold sore patch to acyclovir cream 5% in the treatment of herpes simplex labialis

Hydrocolloid technology has been proven effective in treating dermal wounds. A previous study showed that a newly developed thin hydrocolloid patch [Compeed cold sore patch (CSP)] provided multiple wound-healing benefits across all stages of a herpes simplex labialis (HSL) outbreak. An assessment of CSP efficacy and safety was conducted in an international, multicentre, assessor-blinded study, which enrolled 728 subjects with a history of recurrent HSL. Of these, 351 experienced an HSL outbreak and were randomized to use CSP (n = 179) or acyclovir cream 5% (n = 172) at the onset of symptoms until the lesion healed, for a maximum of 10 days. The primary end point was the subject's global assessment of therapy (SGAT; 0-10 scale; 0 = no response, 10 = excellent response). Multiple secondary end points included clinician-assessed healing time and subject assessment of lesion protection, noticeability and social embarrassment. CSP and acyclovir were highly effective (mean SGAT = 7.89 and 8.00, respectively), with no significant difference observed (P = 0.65). The difference in healing times between products was not significant (median, 7.57 days with CSP vs. 7.03 days with acyclovir, P = 0.37). Both treatments were well tolerated. CSP using hydrocolloid technology provides an efficacious and safe alternative to topical antivirals in treating HSL as a wound while affording additional immediate benefits of wound protection, discretion and relief of social embarrassment.

Treatment of herpes simplex labialis with low power laser therapy.

Introduction: Herpes simplex is caused by Herpes virus hominis, producing an acute eruptive affection marked by groups of vesicles on the skin, often on the borders of the lips or nares (cold sores) or on the genitals (genital herpes); it often accompanies fever (fever blisters, herpes febrilis). Objective: Effectiveness of the treatment with low power laser therapy was evaluated against the conventional treatment in people assisting to the clinical evolution, disappearance of symptoms and signs in patients with herpes simplex labialis. Methods: The sample was constituted by 60 patients attending the consultation of dermatology for this entity, in four policlinics of the Cuban capital during 2006. It was carried out an explanatory study of experimental and prospective type; two types of treatments were applied, the conventional with acyclovir (either oral or topically) and low power laser therapy (unique treatment). Results: Women prevalence was high 78.3%; the affected age group was 28 and 37 years (45.5%); disappearance of symptoms and signs in the conventional treatment needed 7.3 sessions, while laser therapy needed 5.2 sessions. There were statistically significant differences between both treatments; as for the clinical evolution both treatments had higher percentage of cured patients. It is recommended to evaluate in long periods the presence of relapses and that it is used this treatment technique like an option of treatment’s alternatives to improve the quality of patients’ lives.

Effective treatment of herpes simplex labialis with penciclovir cream: Combined results of two trials

Two randomized, double-blind, parallel-group clinical trials were conducted in Europe and North America to compare the efficacy and safety of topical 1 percent penciclovir cream with a placebo cream. A total of 4,573 immunocompetent people with a history of recurrent herpes simplex labialis, or HSL, with three or more episodes a year that typically manifested as classical lesions, were enrolled and prospectively dispensed medication-either 1 percent penciclovir in a cetomacrogol cream base or a matching placebo. Patients self-initiated treatment and were required to apply study medication six times per day for the first day and every two hours while awake for four consecutive days. Of 4,573 enrolled patients, 3,057 initiated treatment (1,516 with penciclovir and 1,541 with placebo). Combined data from two trials revealed that penciclovir recipients lost classical lesions 31 percent faster than did placebo recipients (hazard ratio, or HR, = 1.31; 95 percent confidence interval, or CI, 1.20 to 1.42; P = .0001) and experienced 28 percent faster resolution of lesion pain (HR = 1.28; 95 percent CI, 1.17 to 1.39; P = .0001). Significant benefits were achieved with penciclovir use whether treatment was initiated in the early stages (P = .001) or later stages (P = .0055). The largest data set currently available on the treatment of recurrent HSL revealed that penciclovir cream significantly outperformed the placebo in healing classical lesions and resolution of pain. The authors found that penciclovir cream positively affects recurrent HSL, and dose frequency is vital to topical treatment. Even when penciclovir was applied late, it was effective in favorably altering the course of recurrent HSL.

Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: A multicenter, randomized, placebo-controlled trial

Background: Recurrent herpes simplex labialis (HSL) occurs in 20% to 40% of the US population. Although the disease is self-limiting in persons with a healthy immune response, patients seek treatment because of the discomfort and visibility of a recurrent lesion. Objective: Our purpose was to determine whether docosanol 10% cream (docosanol) is efficacious compared with placebo for the topical treatment of episodes of acute HSL. Methods: Two identical double-blind, placebo-controlled studies were conducted at a total of 21 sites. Otherwise healthy adults, with documented histories of HSL, were randomized to receive either docosanol or polyethylene glycol placebo and initiated therapy in the prodrome or erythema stage of an episode. Treatment was administered 5 times daily until healing occurred (ie, the crust fell off spontaneously or there was no longer evidence of an active lesion) with twice-daily visits. Results: The median time to healing in the 370 docosanol-treated patients was 4.1 days, 18 hours shorter than observed in the 367 placebo-treated patients (P = .008; 95% confidence interval [CI]: 2, 22). The docosanol group also exhibited reduced times from treatment initiation to (1) cessation of pain and all other symptoms (itching, burning, and/or tingling; P = .002; 95% CI: 3, 16.5); (2) complete healing of classic lesions (P = .023; 95% CI: 1, 24.5); and (3) cessation of the ulcer or soft crust stage of classic lesions (P < .001; 95% CI: 8, 25). Aborted episodes were experienced by 40% of the docosanol recipients versus 34% of placebo recipients (P = .109; 95% CI for odds ratio: 0.95, 1.73). Adverse experiences with docosanol were mild and similar to those with placebo. Conclusion: Docosanol applied 5 times daily is safe and effective in the treatment of recurrent HSL. Differences in healing time compared favorably with those reported for the only treatment of HSL that has been approved by the Food and Drug Administration. (J Am Acad Dermatol 2001;45:222-30.)

Penciclovir cream for the treatment of herpes simplex labialis: A randomized, multicenter, double-blind, placebo-controlled trial: Spruance SL, Rea TL, Thoming C, et al. JAMA 277:1374, 1997

Penciclovir cream for the treatment of herpes simplex labialis: A randomized, multicenter, double-blind, placebo-controlled trial: Spruance SL, Rea TL, Thoming C, et al. JAMA 277:1374, 1997

Influence of the size of the virus inoculum on the efficacy of acyclovir (ACV) and implications for the treatment of herpes simplex labialis: M.B. McKeough and S.L. Spruance, University of Utah, Salt Lake City, Utah, USA

Influence of the size of the virus inoculum on the efficacy of acyclovir (ACV) and implications for the treatment of herpes simplex labialis: M.B. McKeough and S.L. Spruance, University of Utah, Salt Lake City, Utah, USA

Allergic contact dermatitis to dyclonine hydrochloride simulating extensive herpes simplex labialis

Two patients developed allergic contact dermatitis to 1% dyclonine hydrochloride gel, a nonprescription topical anesthetic widely marketed for the symptomatic treatment of herpes simplex labialis. Both patients mistakenly believed that the eruption was expanding herpes simplex labialis, which resulted in their more frequent application of the dyclonine hydrochloride and a delay in diagnosis. Dermatologists should recognize that 1% dyclonine hydrochloride gel can cause allergic contact dermatitis that can masquerade as widespread herpes simplex labialis.

Treatment of herpes simplex labialis with topical acyclovir in polyethylene glycol

Treatment of herpes simplex labialis with topical acyclovir in polyethylene glycol

The potential of phosphonoformate for the treatment of herpex simplex labialis.

The potential of phosphonoformate for the treatment of herpex simplex labialis.